Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study
Open Access
- 7 April 2008
- journal article
- Published by Wiley in Clinical Genetics
- Vol. 73 (5), 430-440
- https://doi.org/10.1111/j.1399-0004.2008.00978.x
Abstract
Progressive skeletal disease accounts for some of the most debilitating complications of type 1 Gaucher disease. In this 48-month, prospective, non-randomized, open-label study of the effect of enzyme replacement therapy on bone response, 33 imiglucerase-naïve patients (median age 43 years with one or more skeletal manifestations such as osteopenia, history of bone crisis, or other documented bone pathology) received imiglucerase 60 U/kg/2 weeks. Substantial improvements were observed in bone pain (BP), bone crises (BC), and bone mineral density (BMD). Improvements in BP were observed at 3 months (p < 0.001 vs baseline) and continued progressively throughout the study, with 39% of patients reporting pain at 48 months vs 73% at baseline. Eleven of the 13 patients with a pre-treatment history of BC had no recurrences. Biochemical markers for bone formation increased; markers for bone resorption decreased. Steady improvement of spine and femoral neck BMD, measured using dual-energy X-ray absorptiometry was noted. Mean Z score for spine increased from −0.72 ± 1.302 at baseline to near-normal levels (−0.09 ± 1.503) by month 48 (p = 0.042) and for femoral neck from −0.59 ± 1.352 to −0.17 ± 1.206 (p = 0.035) at month 36. This increase was sustained at 48 months. With imiglucerase treatment, patients should anticipate resolution of BC, rapid improvement in BP, increases in BMD, and decreased skeletal complications.Keywords
This publication has 26 references indexed in Scilit:
- Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher diseaseClinical Genetics, 2007
- The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher diseaseClinical Genetics, 2007
- Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher DiseaseJournal of Bone and Mineral Research, 2007
- Quality of life related to type 1 Gaucher disease: Spanish experienceQuality of Life Research, 2005
- Bone density changes with enzyme therapy for Gaucher diseaseJournal of Bone and Mineral Metabolism, 2004
- Gaucher disease and bone: Laboratory and skeletal mineral density variations during a long period of enzyme replacement therapyJournal of Inherited Metabolic Disease, 2004
- Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapyBlood, 2004
- The health-related quality of life of adults with Gaucher‘s disease receiving enzyme replacement therapy: results from a retrospective studyQuality of Life Research, 1998
- Enzyme Replacement Therapy for Gaucher Disease: Critical Investigations beyond Demonstration of Clinical EfficacyBiochemical Medicine and Metabolic Biology, 1994
- Skeletal Complications of Gaucher DiseaseMedicine, 1985